Evidence map›Paper›PMID 39623876›Full record

ArticleFuture medicinal chemistry2025

Unlocking the potential of the thioamide group in drug design and development.

Guang Huang, Tomasz Cierpicki, Jolanta Grembecka

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guang HuangDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7226-5743
Tomasz CierpickiDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-2058-0658
Jolanta GrembeckaDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6180-9095

Funding

Development of novel anti-leukemia agents targeting the menin-MLL interactionR01CA160467 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GREMBECKA, JOLANTA · 2011 to 2021
$3.4M
Development of ASH1L inhibitors for acute leukemiaR01CA244254 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GREMBECKA, JOLANTA · 2020 to 2024
$2.8M
Targeting Menin in Acute Leukemia with Upregulated HOX GenesR01CA272561 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jolanta Grembecka · 2023 to 2026
$2.5M
Targeting PRC1 in leukemiaR01CA282082 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Tomasz Cierpicki · 2023 to 2026
$2.5M
Targeting NSD1 in leukemiaR01CA226759 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CIERPICKI, TOMASZ · 2019 to 2023
$2.3M
Screening for inhibitors of NSD3 as a treatment for lung cancerR01CA276074 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jolanta Grembecka · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA160467NCI NIH HHS R01 CA226759NCI NIH HHS R01 CA244254NCI NIH HHS R01 CA272561NCI NIH HHS R01 CA276074NCI NIH HHS R01 CA282082
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bioisosterechelatordrug designdrug discoveryhydrogen sulfide donormetal complexesprodrugThioamides

Identifiers

PMID39623876
PMCPMC11703445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.